Report cover image

Global Peptide and Oligonucleotide CDMO Market Growth (Status and Outlook) 2023-2029

Publisher LP Information, Inc.
Published Aug 02, 2023
Length 111 Pages
SKU # LPI18093414

Description

Global Peptide and Oligonucleotide CDMO Market Growth (Status and Outlook) 2023-2029


According to our (LP Info Research) latest study, the global Peptide and Oligonucleotide CDMO market size was valued at US$ 1565.2 million in 2022. With growing demand in downstream market and recovery from influence of COVID-19 and the Russia-Ukraine War, the Peptide and Oligonucleotide CDMO is forecast to a readjusted size of US$ 3123.4 million by 2029 with a CAGR of 10.4% during review period.

The research report highlights the growth potential of the global Peptide and Oligonucleotide CDMO market. With recovery from influence of COVID-19 and the Russia-Ukraine War, Peptide and Oligonucleotide CDMO are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Peptide and Oligonucleotide CDMO. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Peptide and Oligonucleotide CDMO market.

Key Features:

The report on Peptide and Oligonucleotide CDMO market reflects various aspects and provide valuable insights into the industry.

Market Size and Growth: The research report provide an overview of the current size and growth of the Peptide and Oligonucleotide CDMO market. It may include historical data, market segmentation by Type (e.g., Peptide CDMO, Oligonucleotide CDMO), and regional breakdowns.

Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Peptide and Oligonucleotide CDMO market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.

Competitive Landscape: The research report provides analysis of the competitive landscape within the Peptide and Oligonucleotide CDMO market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

Technological Developments: The research report can delve into the latest technological developments in the Peptide and Oligonucleotide CDMO industry. This include advancements in Peptide and Oligonucleotide CDMO technology, Peptide and Oligonucleotide CDMO new entrants, Peptide and Oligonucleotide CDMO new investment, and other innovations that are shaping the future of Peptide and Oligonucleotide CDMO.

Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Peptide and Oligonucleotide CDMO market. It includes factors influencing customer ' purchasing decisions, preferences for Peptide and Oligonucleotide CDMO product.

Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Peptide and Oligonucleotide CDMO market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Peptide and Oligonucleotide CDMO market. The report also evaluates the effectiveness of these policies in driving market growth.

Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Peptide and Oligonucleotide CDMO market.

Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Peptide and Oligonucleotide CDMO industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.

Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Peptide and Oligonucleotide CDMO market.

Market Segmentation:

Peptide and Oligonucleotide CDMO market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Segmentation by type
Peptide CDMO
Oligonucleotide CDMO

Segmentation by application
Pharmaceutical and Biotechnology Companies
Research Institutes
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Lonza Group Ltd.
Thermo Fisher Scientific Inc.
Merck KGaA
Catalent, Inc.
Genscript Biotech Corporation
Polypeptide Group
Bachem Holding AG
Wuxi Apptec Co., Ltd.
Ajinomoto Co., Inc.
Rentschler Biopharma SE
Corden Pharma GmbH
Senn Chemicals AG
Almac Group
Lonza Custom Manufacturing
Creative Peptides
Swiss Customized Synthesis
Syngene
Eurogentec

Please note: The report will take approximately 2 business days to prepare and deliver.

Table of Contents

111 Pages
*This is a tentative TOC and the final deliverable is subject to change.*
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Peptide and Oligonucleotide CDMO Market Size 2018-2029
2.1.2 Peptide and Oligonucleotide CDMO Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Peptide and Oligonucleotide CDMO Segment by Type
2.2.1 Peptide CDMO
2.2.2 Oligonucleotide CDMO
2.3 Peptide and Oligonucleotide CDMO Market Size by Type
2.3.1 Peptide and Oligonucleotide CDMO Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2023)
2.4 Peptide and Oligonucleotide CDMO Segment by Application
2.4.1 Pharmaceutical and Biotechnology Companies
2.4.2 Research Institutes
2.4.3 Others
2.5 Peptide and Oligonucleotide CDMO Market Size by Application
2.5.1 Peptide and Oligonucleotide CDMO Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2018-2023)
3 Peptide and Oligonucleotide CDMO Market Size by Player
3.1 Peptide and Oligonucleotide CDMO Market Size Market Share by Players
3.1.1 Global Peptide and Oligonucleotide CDMO Revenue by Players (2018-2023)
3.1.2 Global Peptide and Oligonucleotide CDMO Revenue Market Share by Players (2018-2023)
3.2 Global Peptide and Oligonucleotide CDMO Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Peptide and Oligonucleotide CDMO by Regions
4.1 Peptide and Oligonucleotide CDMO Market Size by Regions (2018-2023)
4.2 Americas Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023)
4.3 APAC Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023)
4.4 Europe Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023)
4.5 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023)
5 Americas
5.1 Americas Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023)
5.2 Americas Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
5.3 Americas Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Peptide and Oligonucleotide CDMO Market Size by Region (2018-2023)
6.2 APAC Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
6.3 APAC Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Peptide and Oligonucleotide CDMO by Country (2018-2023)
7.2 Europe Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
7.3 Europe Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Peptide and Oligonucleotide CDMO by Region (2018-2023)
8.2 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
8.3 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Peptide and Oligonucleotide CDMO Market Forecast
10.1 Global Peptide and Oligonucleotide CDMO Forecast by Regions (2024-2029)
10.1.1 Global Peptide and Oligonucleotide CDMO Forecast by Regions (2024-2029)
10.1.2 Americas Peptide and Oligonucleotide CDMO Forecast
10.1.3 APAC Peptide and Oligonucleotide CDMO Forecast
10.1.4 Europe Peptide and Oligonucleotide CDMO Forecast
10.1.5 Middle East & Africa Peptide and Oligonucleotide CDMO Forecast
10.2 Americas Peptide and Oligonucleotide CDMO Forecast by Country (2024-2029)
10.2.1 United States Peptide and Oligonucleotide CDMO Market Forecast
10.2.2 Canada Peptide and Oligonucleotide CDMO Market Forecast
10.2.3 Mexico Peptide and Oligonucleotide CDMO Market Forecast
10.2.4 Brazil Peptide and Oligonucleotide CDMO Market Forecast
10.3 APAC Peptide and Oligonucleotide CDMO Forecast by Region (2024-2029)
10.3.1 China Peptide and Oligonucleotide CDMO Market Forecast
10.3.2 Japan Peptide and Oligonucleotide CDMO Market Forecast
10.3.3 Korea Peptide and Oligonucleotide CDMO Market Forecast
10.3.4 Southeast Asia Peptide and Oligonucleotide CDMO Market Forecast
10.3.5 India Peptide and Oligonucleotide CDMO Market Forecast
10.3.6 Australia Peptide and Oligonucleotide CDMO Market Forecast
10.4 Europe Peptide and Oligonucleotide CDMO Forecast by Country (2024-2029)
10.4.1 Germany Peptide and Oligonucleotide CDMO Market Forecast
10.4.2 France Peptide and Oligonucleotide CDMO Market Forecast
10.4.3 UK Peptide and Oligonucleotide CDMO Market Forecast
10.4.4 Italy Peptide and Oligonucleotide CDMO Market Forecast
10.4.5 Russia Peptide and Oligonucleotide CDMO Market Forecast
10.5 Middle East & Africa Peptide and Oligonucleotide CDMO Forecast by Region (2024-2029)
10.5.1 Egypt Peptide and Oligonucleotide CDMO Market Forecast
10.5.2 South Africa Peptide and Oligonucleotide CDMO Market Forecast
10.5.3 Israel Peptide and Oligonucleotide CDMO Market Forecast
10.5.4 Turkey Peptide and Oligonucleotide CDMO Market Forecast
10.5.5 GCC Countries Peptide and Oligonucleotide CDMO Market Forecast
10.6 Global Peptide and Oligonucleotide CDMO Forecast by Type (2024-2029)
10.7 Global Peptide and Oligonucleotide CDMO Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Lonza Group Ltd.
11.1.1 Lonza Group Ltd. Company Information
11.1.2 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product Offered
11.1.3 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Lonza Group Ltd. Main Business Overview
11.1.5 Lonza Group Ltd. Latest Developments
11.2 Thermo Fisher Scientific Inc.
11.2.1 Thermo Fisher Scientific Inc. Company Information
11.2.2 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product Offered
11.2.3 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Thermo Fisher Scientific Inc. Main Business Overview
11.2.5 Thermo Fisher Scientific Inc. Latest Developments
11.3 Merck KGaA
11.3.1 Merck KGaA Company Information
11.3.2 Merck KGaA Peptide and Oligonucleotide CDMO Product Offered
11.3.3 Merck KGaA Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Merck KGaA Main Business Overview
11.3.5 Merck KGaA Latest Developments
11.4 Catalent, Inc.
11.4.1 Catalent, Inc. Company Information
11.4.2 Catalent, Inc. Peptide and Oligonucleotide CDMO Product Offered
11.4.3 Catalent, Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Catalent, Inc. Main Business Overview
11.4.5 Catalent, Inc. Latest Developments
11.5 Genscript Biotech Corporation
11.5.1 Genscript Biotech Corporation Company Information
11.5.2 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product Offered
11.5.3 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Genscript Biotech Corporation Main Business Overview
11.5.5 Genscript Biotech Corporation Latest Developments
11.6 Polypeptide Group
11.6.1 Polypeptide Group Company Information
11.6.2 Polypeptide Group Peptide and Oligonucleotide CDMO Product Offered
11.6.3 Polypeptide Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Polypeptide Group Main Business Overview
11.6.5 Polypeptide Group Latest Developments
11.7 Bachem Holding AG
11.7.1 Bachem Holding AG Company Information
11.7.2 Bachem Holding AG Peptide and Oligonucleotide CDMO Product Offered
11.7.3 Bachem Holding AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Bachem Holding AG Main Business Overview
11.7.5 Bachem Holding AG Latest Developments
11.8 Wuxi Apptec Co., Ltd.
11.8.1 Wuxi Apptec Co., Ltd. Company Information
11.8.2 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product Offered
11.8.3 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Wuxi Apptec Co., Ltd. Main Business Overview
11.8.5 Wuxi Apptec Co., Ltd. Latest Developments
11.9 Ajinomoto Co., Inc.
11.9.1 Ajinomoto Co., Inc. Company Information
11.9.2 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product Offered
11.9.3 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Ajinomoto Co., Inc. Main Business Overview
11.9.5 Ajinomoto Co., Inc. Latest Developments
11.10 Rentschler Biopharma SE
11.10.1 Rentschler Biopharma SE Company Information
11.10.2 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product Offered
11.10.3 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Rentschler Biopharma SE Main Business Overview
11.10.5 Rentschler Biopharma SE Latest Developments
11.11 Corden Pharma GmbH
11.11.1 Corden Pharma GmbH Company Information
11.11.2 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product Offered
11.11.3 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Corden Pharma GmbH Main Business Overview
11.11.5 Corden Pharma GmbH Latest Developments
11.12 Senn Chemicals AG
11.12.1 Senn Chemicals AG Company Information
11.12.2 Senn Chemicals AG Peptide and Oligonucleotide CDMO Product Offered
11.12.3 Senn Chemicals AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Senn Chemicals AG Main Business Overview
11.12.5 Senn Chemicals AG Latest Developments
11.13 Almac Group
11.13.1 Almac Group Company Information
11.13.2 Almac Group Peptide and Oligonucleotide CDMO Product Offered
11.13.3 Almac Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Almac Group Main Business Overview
11.13.5 Almac Group Latest Developments
11.14 Lonza Custom Manufacturing
11.14.1 Lonza Custom Manufacturing Company Information
11.14.2 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product Offered
11.14.3 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Lonza Custom Manufacturing Main Business Overview
11.14.5 Lonza Custom Manufacturing Latest Developments
11.15 Creative Peptides
11.15.1 Creative Peptides Company Information
11.15.2 Creative Peptides Peptide and Oligonucleotide CDMO Product Offered
11.15.3 Creative Peptides Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Creative Peptides Main Business Overview
11.15.5 Creative Peptides Latest Developments
11.16 Swiss Customized Synthesis
11.16.1 Swiss Customized Synthesis Company Information
11.16.2 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product Offered
11.16.3 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 Swiss Customized Synthesis Main Business Overview
11.16.5 Swiss Customized Synthesis Latest Developments
11.17 Syngene
11.17.1 Syngene Company Information
11.17.2 Syngene Peptide and Oligonucleotide CDMO Product Offered
11.17.3 Syngene Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 Syngene Main Business Overview
11.17.5 Syngene Latest Developments
11.18 Eurogentec
11.18.1 Eurogentec Company Information
11.18.2 Eurogentec Peptide and Oligonucleotide CDMO Product Offered
11.18.3 Eurogentec Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.18.4 Eurogentec Main Business Overview
11.18.5 Eurogentec Latest Developments
12 Research Findings and Conclusion

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us